A federal judge ruled Monday to block the Trump administration from forcing pharmaceutical companies to list the prices of medication in television advertisements.

A new law in Colorado capping the price of insulin for insured patients at $100 per month has generated interest in other states because the price of the life-saving drug has spiked, lawmakers said.

The hospitalization rate for diabetic ketoacidosis rose by 90 percent among teenagers in the United States entering adulthood, with researchers suggesting the availability of health insurance may have some effect.

Health insurer Cigna said Wednesday it's starting a plan to cut the financial burden of buying insulin for diabetes patients. The company rolled out a plan that cuts the co-pay for the medicine from an average of $41.

Drug maker Eli Lilly announced a lower-priced insulin for patients who use Humalog.

A House committee on Wednesday asked three major insulin manufacturers to explain to explain to lawmakers why the cost of the diabetes drug is on the rise.

Pharma giant Eli Lilly announced Monday it's purchasing Loxo Oncology for $8 billion, in another step to broaden its cancer treatment portfolio.

Albiglutide, a diabetes drug formerly marketed as Tanzeum, resulted in fewer cardiovascular events among type 2 diabetics with existing heart disease in a study in Europe.

A study has revealed a potential explanation for the failure of drugs for Alzheimer's disease in clinical trials, and researchers may have identified a clinically approved drug that could actually succeed at slowing the condition.

The Food and Drug Administration issued a warning that a class of type 2 diabetes drugs in rare cases might cause flesh-eating bacterial infection of genitals.

A failed drug tested on people with osteoarthritis pain might prevent opioid tolerance and physical dependence when used with opioid-based pain medications.

Indiana received federal approval to require some low-income residents to work, study or perform public service to qualify for Medicaid.

Alex Azar, criticized by women's rights groups for comments that life begins at conception, was sworn in Monday as chief of Health and Human Services.

As experimental drugs fail to stop Alzheimer's from destroying memory, experts now wonder if research into the brain disease has gone in the wrong direction.

The U.S. Senate confirmed former pharmaceutical executive Alex Azar as the new head of the Department of Health and Human Services on Wednesday.